Evidence map›Paper›PMID 36119181›Full record

ArticleJournal of family medicine and primary care2022

Resurgence of hypertension and cardiovascular diseases in patients recovered from COVID-19: An Indian perspective.

Bhaskaran Krishnakumar, Johann Christopher, P Sunil Prasobh, Shreerang Godbole, Anurag Mehrotra, Anurag Singhal, Satrajit Roy, Kuntal Bhattacharya, Narendra Kolte, Mahesh V Abhyankar and 1 more

Open access · goldAbstract read
In one paragraph

Article in Journal of family medicine and primary care, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Bhaskaran KrishnakumarDepartment of Cardiology, Medical College Hospital, Trivandrum, Kerala, India.
Johann ChristopherDepartment of Cardiology, Care Hospital, Banjara Hills, Hyderabad, Telangana, India.
P Sunil PrasobhDepartment of Internal Medicine, Government Medical College, Kollam, Kerala, India.
Shreerang GodboleDepartment of Medicine, Instride Clinic, Shivaji Nagar, Pune, Maharashtra, India.
Anurag MehrotraDepartment of Medicine, Siddh Hospital, Moradabad, Uttar Pradesh, India.
Anurag SinghalDepartment of Medicine, Ajanta Heart Care and Diagnostic Centre, Ghaziabad, Uttar Pradesh, India.
Satrajit RoyDepartment of Medicine, Shree Nursing Home, Asansol, West Bengal, India.
Kuntal BhattacharyaDepartment of Cardiology, RNT Hospital, Kolkata, West Bengal, India.
Narendra KolteDepartment of Medicine, Gurukripa Clinic and Nursing Home, Chandrapur, Maharashtra, India.
Mahesh V AbhyankarScientific Services, USV Private Limited, Mumbai, Maharashtra, India.
Santosh RevankarScientific Services, USV Private Limited, Mumbai, Maharashtra, India.
USV (India) · INCARE Hospitals · INGovernment Medical College · INMedical College and Hospital, Kolkata · INTeerthanker Mahaveer University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: The aim of this study was to understand the prevalence, extent, clinical approach of hypertension and cardiovascular disease (CVD) in patients recovered from COVID-19. Methods: The round table meetings (RTMs) and survey convened a diverse panel of specialists including cardiologists, endocrinologists, diabetologists, consultant physicians, and family physicians from various geographical zones of India. A standard questionnaire including 10 questions was developed pertaining to the resurgence of hypertension and CVD in patients recovered from COVID-19. The RTMs and survey were held virtually. The collected opinions and recommendations were compiled to derive a consensus document. Results: A total of 3066 health-care practitioners (HCPs) participated. Hypertension was the most prevalent comorbidity in patients recovered from COVID-19 followed by diabetes, dyslipidemia, and coronary artery disease. Almost two-thirds of HCPs reported that 10%-30% newly diagnosed hypertension in patients recovered from COVID-19. Uncontrolled hypertension in 10-20% of COVID-19 recovered patients opined by 45% of the HCPs. About, 35% HCPs reported CV complications in 10-20% of Covid-19 recovered patients and 63% HCPs reported exacerbations of CAD in 10-30% of patients. Majority of HCPs preferred to switch to dual combination therapy from monotherapy for hypertension management (52.0%) and ARBs and its combination is most preferred combination for hypertension control (60%). Majority of the HCPs suggested follow-up after 1-2 weeks (39.0%). Close monitoring on symptoms including chest pain and breathlessness (45.0%), adherence to medication and regular monitoring of lab parameters (25%) is recommended for these patients. Conclusion: Overall observations indicate an increased incidence of hypertension and CVDs post recovery from COVID-19. A dual therapy of ARBs was the preferred choice for management of hypertension. Regular follow-up and close monitoring of symptoms to prevent further CV complications in COVID-19 recovered patients is recommended.

Indexed as

Cardiovascularcoronavirusdiabetesdyslipidemiahypertension

Identifiers

PMID36119181
PMCPMC9480725
OpenAlexW4285163729

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.